MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Long-Term Debt 2011-2026 | VNRX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.95 M | 3.62 M | 2.78 M | 2.27 M | 3.45 M | 3.1 M | 3.02 M | 2.38 M | 1.52 M | 548 K | 352 K | 430 K | 640 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.95 M | 352 K | 2.16 M |
Quarterly Long-Term Debt VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.57 M | 5.77 M | 5.53 M | 3.95 M | 3.84 M | 3.87 M | 3.37 M | 3.62 M | 2.09 M | 2.45 M | 2.55 M | 2.78 M | 2.28 M | 1.74 M | 2.03 M | 2.27 M | 2.03 M | 2.22 M | 2.39 M | 2.61 M | 2.61 M | 2.61 M | 2.61 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 1.98 M | 1.98 M | 1.98 M | 1.98 M | 1.31 M | 1.31 M | 1.31 M | 1.31 M | 432 K | 432 K | 432 K | 432 K | 20.4 K | 83.3 K | 264 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.77 M | 20.4 K | 2.26 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
BioNano Genomics
BNGO
|
3.54 M | $ 1.12 | -0.88 % | $ 1.42 M |  USA |
 |
Brainsway Ltd.
BWAY
|
2.08 M | $ 24.41 | 1.2 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
18.3 M | $ 27.63 | -4.06 % | $ 297 M |  China |
 |
Aspira Women's Health
AWH
|
2.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | USA |
 |
Celcuity
CELC
|
105 M | $ 105.79 | 0.61 % | $ 4.17 B | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
 |
Danaher Corporation
DHR
|
18.4 B | $ 209.19 | - | $ 149 B | USA |
 |
DarioHealth Corp.
DRIO
|
24.6 M | $ 11.26 | - | $ 319 M | Israel |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
360 K | $ 23.09 | 0.35 % | $ 698 M | USA |
 |
Co-Diagnostics
CODX
|
2.15 M | - | - | $ 79.8 M | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
5.62 B | $ 209.54 | - | $ 23.3 B | USA |
 |
Castle Biosciences
CSTL
|
9.74 M | $ 29.94 | 3.46 % | $ 832 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
28.3 M | $ 19.25 | 2.45 % | $ 1.03 B | USA |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
53.8 M | $ 73.09 | -0.23 % | $ 28.5 B | USA |
 |
Interpace Biosciences
IDXG
|
1.18 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
6.4 M | $ 103.45 | 0.06 % | $ 19.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 287.13 | 0.64 % | $ 23.9 B | USA |
 |
Guardant Health
GH
|
1.5 B | $ 95.4 | 1.04 % | $ 12 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.34 B | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
2.14 B | $ 166.06 | - | $ 8.23 B | USA |
 |
Myriad Genetics
MYGN
|
120 M | $ 4.43 | 1.14 % | $ 410 M | USA |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.4 B | $ 104.09 | -0.54 % | $ 8.59 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
366 K | $ 3.86 | 2.93 % | $ 2.07 M | USA |
 |
IDEXX Laboratories
IDXX
|
375 M | $ 649.23 | 4.19 % | $ 52.2 B | USA |
 |
Illumina
ILMN
|
554 M | $ 122.9 | 1.96 % | $ 19.5 B | USA |
 |
Natera
NTRA
|
282 M | $ 209.53 | 0.09 % | $ 20.6 B | USA |
 |
IQVIA Holdings
IQV
|
13.9 B | $ 164.88 | - | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
2.09 B | $ 1 379.66 | - | $ 28.4 B |  Schweiz |
|
Biodesix
BDSX
|
40 M | $ 13.02 | 1.96 % | $ 1.69 B | USA |
 |
Quidel Corporation
QDEL
|
101 M | $ 21.93 | 3.49 % | $ 924 M | USA |
 |
Pacific Biosciences of California
PACB
|
31.6 M | $ 1.66 | 5.06 % | $ 421 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 31.5 | 0.9 % | $ 20 B | Niderland |
 |
Lantheus Holdings
LNTH
|
565 M | $ 73.61 | 0.26 % | $ 5.09 B | USA |
 |
Biomerica
BMRA
|
100 K | $ 2.1 | - | $ 4.82 M | USA |